Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation

13 Aug 2020

Abstract excerpt

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases that are considered to be on the same disease spectrum because of overlapping genetic, pathological and clinical traits. Changes in serum proteins in FTD and ALS are poorly understood, and currently no definitive biomarkers exist for diagnosing or monitoring disease progression for either disease. Here we applied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Cholinesterase and Neurodegenerative Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32792518
DOI: 10.1038/s41598-020-70687-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulationPMID 32792518Read ↗

Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosisSemantic proximity Read ↗

Proteomic profiling of CSF reveals stage-specific changes in Amyotrophic lateral sclerosis patientsSemantic proximity Read ↗

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s diseaseSemantic proximity Read ↗

The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of ProteomicsSemantic proximity Read ↗

Network Analysis of the Cerebrospinal Fluid Proteome Reveals Shared and Unique Differences Between Sporadic and Familial Forms of Amyotrophic Lateral SclerosisSemantic proximity Read ↗

A genetic and proteomic comparison of key AD biomarkers across tissuesSemantic proximity Read ↗

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s diseaseSemantic proximity Read ↗

Proteome-wide association study identifies novel Alzheimer's disease- associated proteinsSemantic proximity Read ↗

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read ↗

Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisSemantic proximity Read ↗

Neuroanatomical Quantitative Proteomics Reveals Common Pathogenic Biological Routes between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)Semantic proximity Read ↗

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.